enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. SGLT2 inhibitor - Wikipedia

   en.wikipedia.org/wiki/SGLT2_inhibitor

   Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors ...

3. Sotagliflozin - Wikipedia

   en.wikipedia.org/wiki/Sotagliflozin

   Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. [1] It is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. [1]

4. Drugs like Ozempic may help lower 2nd stroke, heart attack risk

   www.aol.com/drugs-ozempic-may-help-lower...

   “SGLT2 inhibitors’ direct effects on the kidneys relate to blood pressure reduction, which has cardioprotective effects, especially in heart failure — increasing the efficiency of heart ...

5. Empagliflozin - Wikipedia

   en.wikipedia.org/wiki/Empagliflozin

   The main efficacy measurement was the time to death from cardiovascular causes or need to be hospitalized for heart failure. [33] Of the individuals who received empagliflozin for an average of about two years, 14% died from cardiovascular causes or were hospitalized for heart failure, compared to 17% of the participants who received the ...

6. Pairing Drugs Like Ozempic with SGLT2 Meds May Help ... - AOL

   www.aol.com/pairing-drugs-ozempic-sglt2-meds...

   In a meta-analysis involving more than 70,000 patients with diabetes, SGLT2 inhibitors reduced the risk of heart attack, stroke, and kidney disease progression. When paired with a GLP-1 drug, the ...

7. Type 2 diabetes drugs could lower dementia, Parkinson's ... - AOL

   www.aol.com/type-2-drugs-could-lower-133000670.html

   “SGLT2 inhibitors reduce common risk factors associated with dementia and Parkinson’s disease, such as hyperglycemia, insulin resistance, obesity, hypertension, and heart failure.These factors ...